Abstract 1573P
Background
Concurrent chemoradiation is standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC), while the optimal regimen of radiotherapy, especially in terms of total dose and planned range of target field, remained unclear. We performed this phase III clinical trial (ChiCTR-IPR-15007172) to compare the survival benefits between different radiation dose and different target field.
Methods
This trial compared two radiation treatment aspects of total dose and field under two-by-two factorial design. The involved field irradiation (IFI) group and elective nodal irradiation (ENI) group adopted different radiation plans of clinical target volume. The high radiation dose group (HD) totally received 59.4Gy radiation and standard dose group (SD) received 50.4 Gy. The participants were assigned to one of the four groups (HD+ENI, HD+IFI, SD+ENI and SD+IFI) by simple randomization (1:1:1:1 ratio). The planned sample size was 147 in each arm (588 totally) and the primary endpoint was overall survival (OS). All statistical analysis was performed according to intention-to-treat principle.
Results
The median follow-up time reached 64.6 months up to April 2023. In comparison of target field, patients in IFI or ENI presented similar OS (HR=0.99, log rank test p =0.93) and PFS (HR=1.02). The HD treatment did not present significantly prolonged OS (HR=0.90, log rank test p value=0.318) compared with SD but suggested improved PFS (25.2 months to 18.0 months, HR=0.76). No significant synergistic effect was detected between dose and radiation field in interaction analysis (p=0.11). In subgroup analysis, the HD radiation suggested benefits in T4 tumors, and the ENI treatment was associated with better OS in N0 patients. No significant difference in occurrences of severe adverse events was detected in dose or field comparisons.
Conclusions
The IFI has similar treatment efficiency to ENI, which indicated a reasonable choice for locally advanced ESCC. HD radiation did not suggest significant benefits in OS, but associated with better PFS compared to SD.
Clinical trial identification
ChiCTR-IPR-15007172.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the grants of Key Research and Development Program of Shandong Province of China, 2017CXZC1206, National Natural Science Foundation of China, 81874224, Academic promotion program of Shandong First Medical University, China, 2019LJ004, Key Research and Development Program of Shandong Province, 2021LCZX04 and Key Research and Development Program of Shandong Province, 2021SFGC0501.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1645P - STAT3, ACTA2, and SPARC stromal markers predict response to Gemcitabine/Cisplatin/Nab-paclitaxel (GCN) in patients with advanced pancreatic adenocarcinoma (apdac)
Presenter: Himil Mahadevia
Session: Poster session 22
1646P - Genomic and prognostic differences in patients with different KRAS mutations in pancreatic cancer
Presenter: Chunwei Xu
Session: Poster session 22
1647P - Cancer-associated endocrine cell: A novel component of tumor microenvironment in pancreatic cancer
Presenter: Yuan Chen
Session: Poster session 22
1648P - Association between circulating tumor cell count and thrombosis in pancreatic cancer
Presenter: Monica Benavente
Session: Poster session 22
1649P - Comprehensive genomic profiling contributes to the prognosis of patients with advanced pancreatic cancer
Presenter: Eiichiro So
Session: Poster session 22
1650P - Identification of potential targets in pancreatic adenocarcinoma: The KRAS Wild-Type subset
Presenter: Daniel Acosta Eyzaguirre
Session: Poster session 22
1651P - Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy
Presenter: Saad Anwar
Session: Poster session 22
1652P - Interaction between enhanced cytokine signalling and ferroptosis defence fuels obesity-associated pancreatic ductal adenocarcinoma oncogenesis
Presenter: Rishat Ruzi
Session: Poster session 22
1653P - The activated thermogenesis of intra-pancreatic fat fuels the progression of pancreatic cancer
Presenter: Xi'n'peng Yin
Session: Poster session 22
1654P - Circulating tumor cells (CTCs) as prognostic factor for pancreatic cancer: Updated of a prospective study
Presenter: Natalia Gutierrez Alonso
Session: Poster session 22